Why the study?
Does beta-adrenergic receptor blockade affect Alzheimer's disease?
Does beta-adrenergic receptor blockade affect Alzheimer's disease?
This review highlights the complex and controversial genetic and molecular links between beta-adrenergic receptor blockade and Alzheimer's disease.
Answers are grounded in this paper and cite their sources.
Should not alter beta-blocker use in Alzheimer's patients; leaves open targeted trials on genetic-molecular pathways.
According to genetic studies, Alzheimer's disease (AD) is linked to beta-adrenergic receptor blockade through numerous factors, including human leukocyte antigen genes, the renin-angiotensin system, poly(adenosine diphosphate-ribose) polymerase 1, nerve growth factor, vascular endothelial growth factor, and the reduced form of nicotinamide adenine dinucleotide phosphate. Beta-adrenergic receptor blockade is also implicated in AD due to its effects on matrix metalloproteinases, mitogen-activated protein kinase pathways, prostaglandins, cyclooxygenase-2, and nitric oxide synthase. Beta-adrenergic receptor blockade may also have a significant role in AD, although the role is controversial. Behavioral symptoms, sex, or genetic factors, including Beta 2-adrenergic receptor variants, apolipoprotein E, and cytochrome P450 CYP2D6, may contribute to beta-adrenergic receptor blockade modulation in AD. Thus, the characterization of beta-adrenergic receptor blockade in patients with AD is needed.
No takes yet. Share an insight, caveat, or question.
Lương et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: